Tang, Q., Li, J., Zhang, L., Zeng, S., Bao, Q., Hu, W., He, L., Huang, G., Wang, L., Liu, Y., Zhao, X., Yang, S., Hu, C.

Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression

26 de March de 2025 by Tang, Q., Li, J., Zhang, L., Zeng, S., Bao, Q., Hu, W., He, L., Huang, G., Wang, L., Liu, Y., Zhao, X., Yang, S., Hu, C.

Background
The immunotherapy targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death ligand-1 (PD-L1) has achieved significant breakthroughs, but further improvements are still needed in cancer treatment.

Methods
We i…